We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+48.4%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$858M
AUM Growth
+$272M
(+47%)
Cap. Flow
+$61M
Cap. Flow
% of AUM
7.11%
Top 10 Holdings %
Top 10 Hldgs %
51.45%
Holding
74
New
10
Increased
22
Reduced
15
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$23M |
| 2 |
Krystal Biotech
KRYS
|
+$22.3M |
| 3 |
Glaukos
GKOS
|
+$20.9M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$19.4M |
| 5 |
Genmab
GMAB
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VAPO
Vapotherm, Inc. Common Stock
VAPO
|
+$19.5M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$15.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$11M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$10.2M |
| 5 |
AtriCure
ATRC
|
+$9.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.12% |
| 2 | Communication Services | 3.8% |
| 3 | Energy | 0.29% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
26
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $12.5M | 1.45% |
+192,829
| New | +$11.1M |
|
27
SI-BONE Inc
SIBN
$788M
| $10.7M | 1.24% |
669,460
-9,313
| -1% | -$147K |
|
|
ADVM
28
DELISTED
Adverum Biotechnologies
ADVM
| $9.81M | 1.14% |
46,980
+22,750
| +94% | +$4.03M |
|
29
QuidelOrtho
QDEL
$1.14B
| $8.8M | 1.03% |
39,348
-14,164
| -26% | -$2.22M |
|
|
VAPO
30
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $7.72M | 0.9% |
23,544
-92,718
| -80% | -$19.5M |
|
31
OptimizeRx
OPRX
$114M
| $7.69M | 0.9% |
+590,000
| New | +$6.41M |
|
32
Ionis Pharmaceuticals
IONS
$8.6B
| $7.66M | 0.89% |
129,832
-66,018
| -34% | -$3.67M |
|
|
AMRN
33
Amarin Corp
AMRN
$298M
| $7.44M | 0.87% |
53,773
+15,878
| +42% | +$2.18M |
|
34
Simulations Plus
SLP
$369M
| $7.42M | 0.86% |
123,984
+681
| +0.6% | +$30K |
|
35
Health Catalyst
HCAT
$154M
| $7.3M | 0.85% |
250,401
+239,301
| +2,156% | +$6.61M |
|
|
MYOK
36
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $6.54M | 0.76% |
67,653
-52,442
| -44% | -$4.37M |
|
37
OrthoPediatrics
KIDS
$519M
| $5.29M | 0.62% |
120,773
+539
| +0.4% | +$24.2K |
|
38
Ligand Pharmaceuticals
LGND
$5.76B
| $5.05M | 0.59% |
72,443
+534
| +0.7% | +$33.9K |
|
|
LHCG
39
DELISTED
LHC Group LLC
LHCG
| $2.52M | 0.29% |
14,467
+74
| +0.5% | +$10.9K |
|
40
iShares Biotechnology ETF
IBB
$9.34B
| $2.28M | 0.27% |
16,713
| – | – |
|
41
Invesco S&P SmallCap Health Care ETF
PSCH
$163M
| $2.09M | 0.24% |
51,855
| – | – |
|
42
iShares US Medical Devices ETF
IHI
$3.13B
| $2.01M | 0.23% |
45,480
| – | – |
|
43
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $1.82M | 0.21% |
18,241
| – | – |
|
|
GWPH
44
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $626K | 0.07% |
5,100
-1,300
| -20% | -$147K |
|
45
AbbVie
ABBV
$443B
| $587K | 0.07% |
5,981
+1,867
| +45% | +$164K |
|
|
DYNT
46
DELISTED
Dynatronics Corp
DYNT
| $401K | 0.05% |
91,131
+1,131
| +1% | +$4.47K |
|
47
Sanofi
SNY
$103B
| $339K | 0.04% |
6,650
| – | – |
|
48
Merck
MRK
$322B
| $328K | 0.04% |
4,451
| – | – |
|
49
Novartis
NVS
$297B
| $309K | 0.04% |
3,535
| – | – |
|
50
Johnson & Johnson
JNJ
$618B
| $304K | 0.04% |
2,161
| – | – |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2020 Portfolio in Review
As of Q2 2020, First Light Asset Management held 74 positions worth $858M, up 47% from $586M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
First Light Asset Management deployed $61M of net new capital in Q2 2020, opening 10 new positions and adding to 22 existing holdings. Its largest new stake was Y-mAbs Therapeutics: 607,621 shares worth $26.2M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Communication Services and Energy.
On the sell side, the largest reduction was Vapotherm, Inc. Common Stock, an estimated $19.5M trimmed.
- First Light Asset Management's largest Q2 2020 buy was Y-mAbs Therapeutics: 607,621 shares worth $26.2M.
- First Light Asset Management added most to Glaukos in Q2 2020, an estimated $20.9M increase.
- First Light Asset Management's biggest Q2 2020 reduction was Vapotherm, Inc. Common Stock, cutting an estimated $19.5M.
- First Light Asset Management fully exited Iovance Biotherapeutics in Q2 2020, selling an estimated $15.9M.
- First Light Asset Management's ten largest holdings make up 51% of its $858M portfolio in Q2 2020.
- First Light Asset Management opened 10 new positions and closed 14 in Q2 2020.
- First Light Asset Management's portfolio value rose 47% quarter-over-quarter to $858M.
Based on First Light Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.